External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home 2026 ASCO® Breakthrough
Roche and Genentech at

2026 ASCO® Breakthrough

June 25 - June 27
Singapore, Singapore
conferences.asco.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
04:10 AM
Duration 80mins Singapore, Singapore
INAVO120 Phase 3 trial: Subgroup analysis from Asian patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib▼ (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV)
Yoon Sim Yap, Huiping Li, Qingyuan Zhang, Patrapim Sunpaweravong, Roland Ching-Yu Leung, Chayanee Samdaengpan, Chi-Feng Chung, Xiaojia Wang, Kyung Hae Jung, Hooi Lay Teh, Ling-Ming Tseng, Neville Chua, Yanling Jin, Tiffany D Clark, Seock-Ah Im
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.